Idraparinux versus standard therapy for venous thromboembolic disease. - Wikidata - awgldk - TriplyDB

Idraparinux versus standard therapy for venous thromboembolic disease.

Idraparinux versus standard therapy for venous thromboembolic disease.

http://www.wikidata.org/entity/Q34687116

about

Idraparinux or idrabiotaparinux for long-term venous thromboembolism treatment: a systematic review and meta-analysis of randomized controlled trials Pentasaccharides for the treatment of deep vein thrombosis Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism New parenteral anticoagulants in development.Pharmacotherapy with oral Xa inhibitors for venous thromboembolism.Pentasaccharides for the prevention of venous thromboembolism.Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results.Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review Characterization of the plasma and blood anticoagulant potential of structurally and mechanistically novel oligomers of 4-hydroxycinnamic acids Role of factor xa inhibitors in cancer-associated thrombosis: any new data?Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis.Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study.Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database.Factor XI antisense oligonucleotide for prevention of venous thrombosis.Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial.Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach.New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.Lessons learned from the contamination of heparin.Treatment of venous thromboembolism - effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.Rivaroxaban for the treatment of pulmonary embolism.Advantages of a Warfarin Protocol for Long-term Care Pharmacists: a Retrospective Cohort Study.Use of anticoagulants in elderly patients: practical recommendations Respiratory review of 2013: pulmonary thromboembolism.Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies.Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point design.A pharmacogenetic versus a clinical algorithm for warfarin dosing.Emerging drugs for venous thromboembolism.The quest for new anticoagulants: from clinical development to clinical practice.Future of anticoagulant therapy.Alternatives to warfarin--the next generation of anticoagulants.Treatment of thromboembolism in cancer patients.Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond.Emerging anticoagulants.

P2860

Q21090694-51646D6E-88C8-4A57-A136-007C6C92EF86 Q24186811-B1412FD9-B1E6-4F57-BC63-DCB955C2761B Q24633053-BD72B7E3-256C-4E0B-82F0-4F23B2584FB5 Q26828817-BB4ED953-F7C1-4804-9BDB-EFADB393C95E Q27001528-DDD53B99-EE3D-4AFA-9422-6A30A42AA37F Q27027477-9E0CDBA7-1DFE-436E-8D53-EFD2B0D94FF0 Q28087447-4E3A1BEA-53AA-44BC-A08A-07525CF2DE94 Q33392647-9DC8A78C-BEBC-49D6-B262-387225DAF608 Q33419567-46BF2B98-1EEF-4C8E-A2BC-9146C44C8928 Q33436419-887E5445-31E6-466C-B7F5-13F25F3D8647 Q33663404-799D2C2C-3561-40E9-9759-E0A4D27AE163 Q33795571-DB56B6A4-4D62-4522-97BB-0D061A2DE8C2 Q33899404-193158AF-6868-4F46-A806-985BAFBD90CC Q34052232-E7735302-524F-415C-BD1A-4676EE715EBC Q34437785-F96BCAB5-8CC8-479D-A69E-EC5779F4AA30 Q34640824-60C83CB4-80BC-4FB6-8790-5D9A08BBF426 Q35154171-C9E17E7C-3468-46AA-978C-56EAFFB866C4 Q35184566-B3D29BEF-2E68-494A-A5CA-5C12F807EAB8 Q35200286-F9B3D6E4-305E-4194-BF35-32254F27EAE6 Q35555922-2F832D9E-F683-433F-933F-71705D92525E Q35664152-9F7E56DA-8FF2-4F55-B0EC-D7687ED71FD1 Q35752611-9E582C27-0D8B-4D4C-A3B9-239C37ADD63D Q36276886-8D8D3DF4-BF5D-49BB-B0E5-816E6CB55E60 Q36399734-F2CB9CFE-92CE-4776-9A8A-481714BA7903 Q36561057-689F5262-6CEC-4831-8654-DE9D0F964E0B Q36839479-2CD5D7FC-0AD6-490A-B8A0-978642E31B32 Q36997736-B67A0D5D-9CE2-45D1-A72D-00A7D59DFF06 Q37041369-040547E1-C26D-4491-91E8-1EDA1C261CF2 Q37199934-C5042854-8BCE-4301-8C63-E4F1C82E7F7A Q37213987-7E4F3187-62D9-4E40-AEFA-D735041492B9 Q37363885-C3A73609-4D13-44EA-A4A5-CBD627BAA881 Q37406871-8D751019-494B-46BF-AC03-CD9F30343EBD Q37616712-8DB59E1A-D1A2-4B57-BF9C-082B5E072CFC Q37674632-3B9908B9-A374-4459-AAE1-C5EC91AA4D29 Q37765619-2AEAD2A7-0E74-4F4D-8E47-D0B696330144 Q37772194-353D2E4B-2339-40D0-A726-018D5A67C879 Q37772227-EF7FEF30-C44D-4D1F-A748-AC8152902338 Q37773994-76C80D9E-B9B0-4C18-B7C5-3B8C8D841A1A Q37810063-BCD6F170-4F95-482D-B753-B8D8CF992819 Q37847175-4DC4A8AB-FC3C-4C49-A217-7ED197967764

P2860

Idraparinux versus standard therapy for venous thromboembolic disease.

http://www.wikidata.org/entity/Q34687116

description

2007 nî lūn-bûn

@nan

2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Idraparinux versus standard therapy for venous thromboembolic disease.

@ast

Idraparinux versus standard therapy for venous thromboembolic disease.

@en

Idraparinux versus standard therapy for venous thromboembolic disease.

@nl

type

label

Idraparinux versus standard therapy for venous thromboembolic disease.

@ast

Idraparinux versus standard therapy for venous thromboembolic disease.

@en

Idraparinux versus standard therapy for venous thromboembolic disease.

@nl

prefLabel

Idraparinux versus standard therapy for venous thromboembolic disease.

@ast

Idraparinux versus standard therapy for venous thromboembolic disease.

@en

Idraparinux versus standard therapy for venous thromboembolic disease.

@nl

P1433

Q34687116-FFF592FA-0600-4000-B786-5F66182A85DA

P1476

Q34687116-7A904AF9-3B4B-4313-AE68-78862C2ECC0A

P2093

Q34687116-357E2F3A-F669-40FC-B7AB-39A5187A2344

Q34687116-3C58B263-EFA5-40DB-815A-B9A7455336FA

Q34687116-5803F654-3228-4658-8E95-F96911D66D85

Q34687116-7B2CD60D-1B3A-4B8B-A0E2-C6E01CB954A0

Q34687116-A033D22D-4979-48C3-A31B-ACEE9307CD6A

Q34687116-A406207D-6632-4CE7-9E0B-26869BF4C1B8

Q34687116-B9B7285E-B398-4052-9A11-7EA07FD50313

Q34687116-BA48253C-3CB1-4F67-B5A3-D2A54857DECD

Q34687116-C190EB8D-FE0D-475C-9B9C-39275451C33C

Q34687116-D078454B-9186-4451-A992-0F3197D3EE78

P304

Q34687116-BAC3FAB9-F4C8-4608-B8BD-F5C3CD69C50F

P31

Q34687116-C03FDCF1-357E-49A7-AA14-A46AECD6126C

P356

Q34687116-6C696406-B550-4117-92ED-95ABB0325E5B

P407

Q34687116-42B5D127-27ED-453C-A85A-4A2824C0E7B2

P433

Q34687116-4CAC3333-86AD-4523-AE5C-49A9626161A6

P478

Q34687116-F9244193-A285-4EF7-8AB4-6ABEA242001A

P577

Q34687116-1FEA8082-236A-4899-9769-D1D9BB9EB31A

P698

Q34687116-B58BB957-F8DE-434D-875F-6BAC6A47F0D1

P921

Q34687116-E9A39175-9EAF-4946-B597-2F07D8200213

P356

P1433

The New England Journal of Medicine

P1476

Idraparinux versus standard therapy for venous thromboembolic disease.

@en

P2093

Alex S Gallus

http://www.w3.org/2001/XMLSchema#string

Ander T Cohen

http://www.w3.org/2001/XMLSchema#string

Bruce Davidson

http://www.w3.org/2001/XMLSchema#string

Franco Piovella

http://www.w3.org/2001/XMLSchema#string

Gary E Raskob

http://www.w3.org/2001/XMLSchema#string

Gerard Pillion

http://www.w3.org/2001/XMLSchema#string

Harry R Buller

http://www.w3.org/2001/XMLSchema#string

Hervé Decousus

http://www.w3.org/2001/XMLSchema#string

Martin H Prins

http://www.w3.org/2001/XMLSchema#string

Michael Gent

http://www.w3.org/2001/XMLSchema#string

P304

1094-1104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA064247

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

357

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17855670

http://www.w3.org/2001/XMLSchema#string

P921

venous thromboembolism